Our Pricing

Complete Wegovy Dose Journey: 0.25mg to 2.4mg Available

Understanding the wegovy dose escalation schedule uk is essential for achieving optimal weight loss outcomes whilst minimising side effects. At Cured Pharmacy, we provide genuine UK-licensed Wegovy pens across all five dose strengths from £79.00, supported by our UK-registered clinical team who guide you through each stage of your titration journey.

Understanding the Wegovy Dose Escalation Schedule UK

Wegovy (semaglutide) follows a structured dose escalation protocol approved by the MHRA, starting at 0.25mg and gradually increasing to the maintenance dose of 2.4mg over 16 weeks [1]. This gradual titration approach allows your body to adapt to the medication whilst significantly reducing the likelihood of gastrointestinal side effects such as nausea and vomiting.

The standard wegovy dosing schedule progresses through five distinct phases: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally 2.4mg from week 17 onwards as your maintenance dose [1]. Each dose strength is colour-coded on the pen device to prevent administration errors, and our pharmacist Tarun Kumar ensures patients receive clear instructions for each transition.

Clinical data from the STEP 1 trial demonstrated that patients following this complete dose escalation achieved an average 14.9% body weight reduction over 68 weeks, compared to just 2.4% with placebo [1]. The gradual increase is not merely a safety precaution—it's integral to achieving these therapeutic outcomes, as the higher doses produce progressively greater effects on appetite regulation and metabolic function.

Do You Have to Increase Wegovy Dose to 2.4mg?

Whilst the 2.4mg maintenance dose represents the licensed therapeutic target for Wegovy in the UK, dose progression is individualised based on tolerability and clinical response [2]. Some patients may achieve satisfactory weight loss outcomes at lower doses such as 1mg or 1.7mg, particularly if they experience persistent gastrointestinal side effects at higher strengths.

Your UK prescriber will assess your progress at each dose transition, considering factors including weight loss velocity, side effect profile, and overall treatment goals. In clinical practice, approximately 5-10% of patients remain on sub-maintenance doses due to tolerability concerns, though research suggests maximal efficacy occurs at the full 2.4mg dose [2].

If you're unable to tolerate dose escalation despite supportive measures such as dietary modifications and slower titration, your prescriber may consider maintaining you at a lower effective dose rather than discontinuing treatment entirely. However, it's worth noting that the landmark STEP trials specifically evaluated the 2.4mg dose, so the evidence base for long-term efficacy is strongest at this strength [1][2].

When Dose Delays Are Appropriate

Temporary delays in dose escalation may be clinically appropriate if you experience moderate to severe nausea, vomiting, or diarrhoea that doesn't resolve within the first two weeks of a new dose [3]. In such cases, your prescriber might recommend remaining at your current dose for an additional 4 weeks before attempting progression. This flexible approach maintains treatment continuity whilst prioritising your comfort and adherence.

Managing Side Effects During Wegovy Dose Progression

Gastrointestinal side effects peak during the first few days following each dose increase, with nausea being the most commonly reported symptom affecting approximately 44% of patients in clinical trials [3]. These effects typically diminish within 1-2 weeks as your body adapts to the new dose level, and rarely require treatment discontinuation when managed appropriately.

Practical strategies to minimise side effects include eating smaller, more frequent meals, avoiding high-fat foods immediately after injection, staying well-hydrated, and timing your weekly injection for a day when you can rest if needed. Our clinical team at Cured Pharmacy provides personalised guidance on dietary modifications that complement each dose phase, helping you navigate the titration schedule with greater comfort.

If you experience persistent vomiting that prevents adequate fluid intake, severe abdominal pain, or signs of pancreatitis such as radiating back pain, you should contact your prescriber immediately [3]. Whilst serious adverse events are uncommon, occurring in fewer than 5% of trial participants, prompt clinical assessment ensures any complications are identified and managed appropriately.

Injection Site Reactions and Rotation

Rotating your injection site between the abdomen, thigh, and upper arm reduces the risk of lipodystrophy and localised reactions. Each Wegovy pen is pre-filled for single use, making administration straightforward across all dose strengths. Minor injection site reactions such as redness or itching affect fewer than 2% of patients and typically resolve without intervention [3].

Wegovy Maintenance Dose: What to Expect at 2.4mg

Once you reach the 2.4mg maintenance dose at week 17, you'll continue this strength indefinitely as long as the treatment remains effective and well-tolerated [4]. The maintenance phase is where sustained weight loss occurs, with trial data showing continued gradual weight reduction through week 68 rather than a plateau effect [1].

Patients on the 2.4mg maintenance dose in the STEP trials lost an average of 15-17% of their baseline body weight by 68 weeks, with approximately 50% achieving at least 15% weight reduction and 32% achieving 20% or greater reduction [1][4]. These outcomes significantly exceed those achieved with lifestyle interventions alone or older weight management medications.

It's important to maintain realistic expectations during the maintenance phase—weight loss velocity naturally slows after the first 6 months, and minor fluctuations of 1-2kg are normal. Your UK prescriber will monitor your progress through periodic reviews, typically every 3-6 months, assessing not just weight but also improvements in obesity-related comorbidities such as type 2 diabetes, hypertension, and dyslipidaemia [4].

What Happens If You Miss a Wegovy Dose During Escalation?

If you miss a scheduled Wegovy injection and it's been fewer than 5 days since your missed dose, administer it as soon as you remember and continue your regular weekly schedule [5]. However, if more than 5 days have elapsed, skip the missed dose entirely and resume with your next scheduled injection to avoid doubling up.

Missing doses during the escalation phase doesn't necessarily require restarting from 0.25mg, but the decision depends on how long you've been off treatment [5]. If you've missed 2 weeks or less, you can typically resume at your current dose level. Gaps of 3-4 weeks may require stepping back one dose level, whilst interruptions exceeding 4 weeks often necessitate restarting the full titration schedule to minimise side effects.

Our pharmacist Tarun Kumar recommends setting a weekly reminder on your phone for the same day and approximate time each week, which helps maintain consistency and reduces the likelihood of missed doses. If supply interruptions occur, contact Cured Pharmacy immediately—we maintain stock across all Wegovy dose strengths and can often arrange next-day delivery to prevent treatment gaps.

Dose Consistency and Efficacy

Maintaining consistent weekly dosing is crucial for sustaining therapeutic semaglutide levels and achieving optimal weight loss outcomes. Irregular dosing patterns can lead to fluctuating side effects and reduced efficacy, as the medication's appetite-suppressing effects diminish when blood levels drop [5].

Accessing the Complete Wegovy Dose Journey at Cured Pharmacy

At Cured Pharmacy, we stock all five Wegovy dose strengths year-round, ensuring seamless progression through your complete dose escalation schedule without supply-related interruptions. Our transparent pricing starts from £79.00 per pen, with the exact cost determined by your prescribed dose following your free online consultation with a UK-registered prescriber.

The consultation process takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications to semaglutide therapy. Subject to prescriber approval, your Wegovy prescription is dispensed by our GPhC-registered pharmacy (9012511) and dispatched in 100% discreet packaging, typically arriving within 1-2 working days across the UK.

Unlike some providers who only stock certain dose strengths, our comprehensive inventory means you'll never face delays when transitioning between doses. We also provide ongoing clinical support throughout your treatment journey—if you have questions about side effects, dose timing, or progression, our team is available via phone on (+44) 116 4646009 during normal business hours.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Wadden, T. A., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
5. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, used alongside a reduced-calorie diet and increased physical activity. Individual results may vary, and weight loss outcomes depend on adherence to the complete treatment programme including lifestyle modifications.